479690-03-4

Usage

Uses

Used in Pharmaceutical Industry:
Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)-, is used as a potential pharmaceutical candidate for the development of novel drugs due to its unique chemical structure and the presence of functional groups that may confer specific biological properties. Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)-'s potential applications in this industry could include the treatment of various diseases and conditions, depending on its pharmacological profile and therapeutic effects.
Used in Chemical Synthesis:
In the chemical synthesis industry, Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)-, can be used as a building block or intermediate in the synthesis of more complex organic compounds. Its unique structure and functional groups may enable the creation of new molecules with specific properties and applications in various fields, such as materials science, agrochemicals, or specialty chemicals.
Used in Research and Development:
Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)-, is used as a research compound in academic and industrial laboratories to study its chemical properties, reactivity, and potential applications. Researchers may investigate its interactions with biological systems, its ability to modulate specific biological pathways, or its potential as a precursor for the synthesis of other compounds with desired properties.

Upstream product

• 479690-08-9 1-(2-fluoro-4-nitrophenyl)-6-hydroxy-7-methoxy-quinoline 
• 516526-45-7 4-(2-fluoro-4-nitrophenoxy)-7-methoxylquinolyl-6-ol 
• 100-44-7 benzyl chloride 
• 205448-29-9 7-benzyloxy-4-hydroxy-6-methoxyquinoline 
• 369-34-6 3,4-difluoronitrobenzene 
• 205448-29-9 6-methoxy-7-benzyloxy-4(1H)-quinolinone 
• 75167-86-1 2-(benzyloxy)-1-methoxy-4-nitrobenzene 
• 61324-40-1 3-benzyloxy-4-methoxybenzeneamine 
• 636-93-1 5-nitroguaiacol 
• 205448-28-8 5-{[(3-(benzyloxy)-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6- dione 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 75665-88-2 1-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)ethanone 
• 1835-11-6 4-benzyloxy-3-methoxyacetophenone 
• 100-39-0 benzyl bromide 

Downstream Products

• 479690-04-5 4-(7-(benzyloxy)-6-methoxyquinolin-4-yloxy)-3-fluorobenzenamine 
• 479690-08-9 1-(2-fluoro-4-nitrophenyl)-6-hydroxy-7-methoxy-quinoline 
• 929252-63-1 hydrobromide salt of 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-hydroxyquinoline 
• 479690-09-0 3-fluoro-4-{[7-(3-chloropropyl)-6-methoxy-4-quinolyl]oxy}nitrobenzene 
• 1416320-80-3 N'-(3-fluoro-4-{[6-methoxy-7-({1-[(methylamino)-2-oxoethyl]piperidin-4-yl}oxy)quinolin-4-yl]oxy}phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 849217-51-2 N-[3-fluoro-4-[[7-benzyloxy-6-methoxy-quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 849217-50-1 N-[3-fluoro-4-[[7-hydroxy-6-methoxy-quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1292258-07-1 3-fluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)benzenesulfonamide 
• 1292258-23-1 2-chloro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)benzenesulfonamide 
• 1292258-01-5 2,5-dichloro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)benzenesulfonamide 
• 1292258-27-5 2,6-dichloro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)benzenesulfonamide 
• 1292258-10-6 3-chloro-4-fluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)benzenesulfonamide 
• 1192300-04-1 N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-ylethoxy)quinolin-4-yloxy]phenyl}-2-trifluoromethylbenzenesulfonamide 
• 1192300-38-1 N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yloxy]phenyl}-2-trifluoromethylbenzenesulfonamide 

Relevant academic research and scientific papers

QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF

The present invention relates to quinoline or quinazoline compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a prodrug molecule thereof, or a deuterated compound thereof. The compound of the presen

Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer

In this study, a novel series of 4,6,7-trisubstituted quinoline analogues bearing thiazolidinones were designed and synthesized based on our previous study. Among them, the most potent compound 15i, 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-y

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Preparation methods of tyrosine kinase inhibitor XJF007 and its intermediate

The invention discloses preparation methods of tyrosine kinase inhibitor XJF007 with a general structural formula (I) and its intermediate. The preparation method of the tyrosine kinase inhibitor XJF007 employs a collecting synthesis strategy of construct

Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors

The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.

Naphthyridine compound and pharmaceutical composition as well as applications thereof

The invention relates to the field of biological medicines and discloses a naphthyridine compound and a pharmaceutical composition as well as applications thereof. The naphthyridine compound has a structure shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, a pharmaceutically acceptable salt or a prodrug. The naphthyridine compound disclosed by the invention has an anti-tumor effect which is obviously superior to the anti-tumor effect of the prior art. And moreover, the naphthyridine compound disclosed by the invention can treat diseases mediated by protein kinase.

A alkyne generation quinoline derivatives and its preparation and use

The invention discloses alkynylquinoline derivatives, and a preparation method and application thereof. The acetylenoquinoline derivatives are alkynylquinoline compounds as shown in a general formula I which is described in the specification and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof. The invention also provides the preparation method for the derivatives and relates to inhibition activity of the compounds as shown in the formula I to a variety of protein tyrosine kinases (e.g. C-Met and VEGFR). Thus, the compounds can be used as anticancer drugs for treatment of human cancers.

Aryloxy quinoline derivatives and their use in therapy

Disclosed herein are aryloxy quinolines derivatives,and the said compounds are compounds of formula (I) or pharmaceutically acceptable salts thereof or solvates, wherein R1, R2, R3, R4, m, n, X, Z, Ar are defined detailedly in the description. Furthermore, medicaments comprising said compounds or salts as active components and the use for treating conditions and disorders relating to protein-tyrosine kinase receptors, especially c-Met, VEGFR are also described.

Quinoline derivatives (by machine translation)

A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeutic agent for Axl related diseases such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, cancer such as glioma, kidney disease, immune system disease, and circulatory system disease.